

DUROLANE[®] (en) INSTRUCTIONS FOR USE

Contents

Each ml contains:

Hyaluronic acid stabilized	20 mg
Phys sodium chloride solution, pH7	q.s.

Description

DUROLANE[®] is intended to be used for intra-articular injection for the symptomatic treatment of mild to moderate knee or hip osteoarthritis. Additionally, DUROLANE is intended to be used for intra-articular injection for symptomatic treatment of mild to moderate osteoarthritis of indicated synovial joints, and for pain following arthroscopic procedures. It should be injected by an authorized physician, or in accordance with local legislation.

DUROLANE contains 20 mg/ml of stabilized non-animal hyaluronic acid in buffered physiological sodium chloride solution pH 7. DUROLANE is a sterile, transparent viscoelastic gel supplied in a 3 ml glass syringe. The product is for single use only.

Hyaluronic acid is identical in all living organisms. It is a natural polysaccharide that is present throughout the tissues of the body, with particularly high concentrations in the synovial fluid and the skin. DUROLANE is composed of biosynthetically produced hyaluronic acid which has been purified and stabilized. DUROLANE is degraded in the body by the same metabolic pathway as endogenous hyaluronic acid.

Mode of Action

The body's hyaluronic acid constitutes a natural part of the synovial fluid and acts in the joints both as a lubricant of cartilage and ligaments and as a shock absorber. Injections of hyaluronic acid in the joint to restore the viscosity and elasticity can diminish the pain and improve the mobility of the joint.

DUROLANE[®] (fc) MODE D’EMPLOI

Contenu

Chaque ml contient :

Acide hyaluronique stabilisé	20 mg
Solution de chlorure de sodium physiologique, pH 7	q.s.

Description

DUROLANE[®] est destiné à être utilisé dans les injections intra-articulaires pour le traitement symptomatique des arthroses bénignes à modérées du genou ou de la hanche. DUROLANE est également destiné à être utilisé dans les injections intra-articulaires pour le traitement symptomatique des arthroses bénignes à modérées des articulations synoviales indiquées et pour le traitement anti-douleur suivant les interventions arthroscopiques. Ce produit doit être injecté par un médecin autorisé ou conformément à la législation législation en vigueur.

DUROLANE contient 20 mg/ml d'acide hyaluronique d'origine non animale stabilisés dans une solution tampon physiologique de chlorure de sodium ajustée à pH 7. DUROLANE est un gel stérile, viscoélastique et transparent fourni dans une seringue en verre de 3 ml. Le produit est réservé à un usage unique.

L'acide hyaluronique est identique dans tous les organismes vivants. Il s'agit d'un polysaccharide naturel présent dans tous les tissus de l'organisme et dont la concentration est particulièrement élevée dans le liquide synovial et la peau. DUROLANE est composé d'acide hyaluronique, obtenu par biosynthèse, purifié et stabilisé. DUROLANE se dégrade dans l'organisme suivant la même voie métabolique que l'acide hyaluronique endogène.

Mode d'action

L'acide hyaluronique de l'organisme constitue une composante naturelle du liquide synovial et agit dans les articulations en tant que lubrifiant du cartilage et des ligaments et comme amortisseur. Les injections d'acide hyaluronique dans l'articulation pour restaurer la viscosité et l'élasticité peuvent atténuer la douleur et améliorer la mobilité de l'articulation.

Dosage

DUROLANE is a **single injection, single dose** preparation and should only be injected once per treatment course. The recommended dose is 3 ml per knee, or hip joint. The recommended dose is 1-2ml for intermediate joints (e.g. ankle) and approximately 1ml for small synovial joints (e.g. thumb).

Indications

Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers, and toes . DUROLANE is also indicated for pain following joint arthroscopy either in the presence of osteoarthritis or subsequent to general surgical repair within 3 months of the procedure.

Contraindications

None known.

Warnings

• DUROLANE should not be injected if the synovial joint is infected or severely inflamed.

• DUROLANE should not be injected if there is an active skin disease or infection present at or near the injection site.

• DUROLANE should not be injected intravascularly or extra-articularly or in the synovial tissues or capsule.

• Do not resterilize DUROLANE as this may damage the product.

Precautions

• DUROLANE should be used with caution in patients with venous or lymphatic stasis present in the leg.

• DUROLANE has not been tested in pregnant or lactating women or in children.

• A separate syringe of DUROLANE must be used for each individual joint to be treated.

• As with any invasive joint procedure there is a small risk of infection.

• DUROLANE should not be injected if the patient is known to be sensitive to hyaluronic acid based products.

• Local anaesthetics should not be used if the patient is known to be allergic or sensitive to local anaesthetics.

• Injection under fluoroscopic control and with the use of a contrast medium should not be made if the patient is known to be allergic or sensitive to the contrast medium.

• In clinical studies, reinjections in the knee have not been studied with a shorter interval between first and second injection than 6 months.

• Increase in injection pressure may indicate incorrect extra-articular placement of the needle or overfilling of the joint.

• The effectiveness of DUROLANE following arthroscopic procedures for diagnosis or examination purposes only has not been established.

• DUROLANE should be used with caution in patients with pre-existing chondrocalcinosis as injection may lead to an acute attack of the condition.

Adverse Events

The majority of the reported adverse reactions in clinical studies of the knee and hip were described as transient pain, swelling and/or stiffness localized to the joint. These adverse reactions were of mild or moderate intensity and only occasionally required treatment with painkillers or NSAID.

The use of other hyaluronic acid preparations in other joints did not reveal any additional unique adverse events.

None of the other adverse reactions that have been reported were interpreted as acute inflammatory arthritis or allergic reactions and they did not need medical attention in the form of surgical intervention, systemic or intra-articular steroids or antibiotics.

Adverse events must be reported to the local Bioventus representative.

Interactions

The safety and effectiveness of DUROLANE concomitantly with other intra-articular injectables have not been established.

Administration

General administration information

• DUROLANE should only be injected by an authorized physician (or in accordance with local legislation), familiar with intra-articular injection technique for the synovial joint intended to be treated, and in facilities well suited for intra-articular injections.

• DUROLANE should be injected using strict aseptic technique.

• DUROLANE should be injected into the joint cavity only.

• Intra-articular injection in certain synovial joints will require image guidance to ensure accurate placement and avoidance of damage to adjacent vital structures.

• The route for intra-articular injection with or without image guidance should be chosen so that damage to adjacent vital structures is avoided.

• The injection site should be swabbed with alcohol or other suitable antiseptic solution before injection.

• Remove joint effusion, if present, before injecting DUROLANE. The same needle should be used for both removal of effusion and injection of DUROLANE.

• The recommended needle size is 18 to 22 G and with adequate length.

• Use of smaller needles increases pressure required to deliver the product.

Additional information for treatment of synovial joints requiring image guidance

• The intra-articular injection in the hip joint should be given under fluoroscopic control (preferably with a contrast medium) or ultrasonographic control in order to assure correct location of the needle in the joint cavity.

• Guidance of other synovial joints is at the discretion of the treating physician.

• Injection discomfort can be minimized by use of topical freezing agents or subcutaneously delivered local anaesthetics.

• Image guided injection should only be performed by physicians experienced in this type of administrations.

Interactions

L'innocuité et l'efficacité de DUROLANE utilisé en même temps que d'autres produits injectables intra-articulaires n'ont pas été établies.

Administration

Renseignements généraux pour l'administration

• DUROLANE ne doit être injecté que par un médecin autorisé (ou conformément à la législation en vigueur) qui connaît bien les techniques d'injection intra-articulaires dans les articulations synoviales à traiter, et utilisant des installations adaptées aux injections intra-articulaires.

• DUROLANE doit être injecté en suivant une technique aseptique rigoureuse.

• DUROLANE doit être injecté uniquement dans la l'interligne articulaire.

• L'injection intra-articulaire exige d'être guidée par imagerie dans certaines articulations synoviales pour assurer un positionnement précis et ne pas endommager les structures vitales adjacentes.

• Le trajet de l'injection intra-articulaire guidée ou non par imagerie doit être choisi de façon à éviter les structures vitales adjacentes.

• Le point d'injection doit être désinfecté à l'alcool ou avec une autre solution antiseptique appropriée avant l'injection.

• Éliminer, le cas échéant, l'épanchement de l'articulation avant d'injecter DUROLANE. La même aiguille doit être utilisée pour l'élimination de l'épanchement et l'injection de DUROLANE.

• Le calibre d'aiguille recommandé est 18 à 22 G et la longueur doit être adéquate.

• L'utilisation d'aiguilles de diamètre inférieur augmente la pression nécessaire à l'injection du produit.

Renseignements supplémentaires sur le traitement des articulations synoviales guidé par imagerie

• L'injection intra-articulaire dans l'articulation de la hanche doit être effectuée sous contrôle fluoroscopique (de préférence à l'aide d'un produit de contraste) et échographique afin d'assurer le positionnement correct de l'aiguille dans l'interligne articulaire.

• La décision de guider l'injection par imagerie pour les autres articulations synoviales incombe au médecin traitant.

Additional information for treatment post arthroscopy

• Following the arthroscopic procedure, intra-articular injection should be performed outside the sterile field as the exterior of the syringe is not sterile.

• Joints that typically undergo arthroscopic procedures are the knee, hip, and ankle joints.

Please inform your patient that:

• As with any invasive joint procedure it is recommended to avoid strenuous activity (e.g. tennis, jogging or long walks) the first two days after the injection.

• Some transient reactions related to the injection of DUROLANE, such as pain and/or swelling/stiffness of mild to moderate intensity during the first week following the injection can be anticipated. If the symptoms last for more than a week a physician should be contacted.

Performance

• Clinical studies of DUROLANE for osteoarthritis of the knee and hip indicate significant mean benefit, such as improvement in knee and hip pain and physical function versus baseline values at 6 months post treatment.

• Studies investigating repeated treatment in the knee 6 months following the initial injection did not give rise to an increased rate of adverse events.

• Controlled trials of DUROLANE in knee osteoarthritis indicates significant benefits in responder rate over saline and non-inferior results as compared to corticosteroid in a widely adopted effectiveness population of patients.

• Clinical studies of other hyaluronic acid preparations similar to DUROLANE in joints beyond the knee and hip for the treatment of osteoarthritis and post-arthroscopy indicate mean benefits over baseline values. Select studies also showed improvements favoring the hyaluronic acid treated group over that of the control therapy, such as saline and corticosteroids. Improvement in pain and physical function out to 6 months post-treatment were observed.

• The half life of DUROLANE in human knees is approximately four (4) weeks.

How Supplied

DUROLANE is supplied in a 3 ml glass syringe with a Luer-lok fitting, packed in a blister pack. The contents of the syringe are sterile. The exterior of the syringe is not sterile.

DUROLANE is intended for single use and should not be re-sterilized. It should be used immediately after the syringe has been removed from its packaging. If the blister package or syringe is opened or damaged, do not use.

The syringe and any unused material must be discarded immediately after the treatment session and must not be reused due to risk of contamination of the unused material and the associated risks including infections. Disposal should be in accordance with accepted medical practice and applicable national, local or institutional guidelines.

Shelf life and Storage

DUROLANE should be stored, in its original packaging, up to 30 °C. The expiry date is indicated on the package and should not be used beyond that date. Protect from freezing.

Manufacturing site

Q-Med AB
Seminariegatan 21, SE-752 28
Uppsala, Sweden

For

Bioventus LLC
4721 Emperor Blvd Suite 100
Durham, NC 27703 USA

North America: 1-800-396-4325 or 1-919-474-6700
All other countries: +31 (0) 20 653-3967


EC Representative

EMERGO EUROPE
Molenstraat 15
2513 BH The Hauge
The Netherlands

Tel: +31 (0) 70 345-8570
Fax: +31 (0) 70 346-7299

IF THE PACKAGE IS DAMAGED, DO NOT USE

*DUROLANE is a registered trademark of Q-Med AB.
For package insert information visit:
www.durolane.ca



Lieu de fabrication

Q-Med AB
Seminariegatan 21, SE-752 28
Uppsala, Suède

Pour

Bioventus LLC
4721 Emperor Blvd Suite 100
Durham, NC 27703 États-Unis

Amérique du Nord : 1-800-396-4325 ou 1-919-474-6700
Tous les autres pays : +31 (0) 20 653-3967

Représentant de la CE

EMERGO EUROPE
Molenstraat 15
2513 BH La Hays
Pays-Bas

Tél. : +31 (0) 70 345-8570
Télééc. : +31 (0) 70 346-7299

NE PAS UTILISER SI L'EMBALLAGE EST ENDOMMAGÉ

* DUROLANE est une marque déposée de Q-Med AB.
Pour des renseignements sur la notice, consulter :
www.durolane.ca

Symbols on packaging	
	Attention, see instructions for use
	Single use only. Do not reuse
	Expiration Date
	Lot number
	Sterile. The contents of the syringe have been sterilized by using moist heat. The exterior of the syringe is not sterile.
	CE-marked according to MDD 93/42/EEC; 0086 is the number of the notified body.
	Manufacturer
	Authorised representative in the European community.
	Temperature limitation.